Literature DB >> 11512128

Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique.

H J Shim1, E J Lee, S H Kim, S H Kim, M Yoo, J W Kwon, W B Kim, M G Lee.   

Abstract

Various factors influencing the protein binding of DA-8159 to 4% human serum albumin (HSA) were evaluated using an equilibrium dialysis technique at an initial DA-8159 concentration of 5 microg/mL. It took approximately 8 h incubation to reach an equilibrium between 4% HSA and an isotonic phosphate buffer of pH 7.4 containing 3% of dextran ('the buffer') using a Spectra/Por 2 membrane (mol. wt. cut-off: 12,000--14,000) in a water bath shaker kept at 37 degrees C and at a rate of 50 oscillations per min. The extent of binding was dependent on DA-8159 concentrations, HSA concentrations, incubation temperature, buffer pH, and alpha-1-acid glycoprotein (AAG) concentrations. The binding of DA-8159 in heparinized human plasma (93.9%) was significantly higher than in rats (81.4%), rabbits (80.4%), and dogs (82.2%), and this could be due to differences in AAG concentrations in plasma. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11512128     DOI: 10.1002/bdd.238

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  4 in total

1.  Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Jee H Shin; Ka Y Choi; Yu C Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin.

Authors:  Y H Choi; M G Lee
Journal:  Br J Pharmacol       Date:  2006-08-29       Impact factor: 8.739

3.  Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.

Authors:  E Y Oh; S K Bae; J W Kwon; M You; D C Lee; M G Lee
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

4.  Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2.

Authors:  H E Kang; S K Bae; M Yoo; D C Lee; Y G Kim; M G Lee
Journal:  Br J Pharmacol       Date:  2009-02-26       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.